Thursday, May 30, 2013

GSK acquires vaccine developer Okairos

GlaxoSmithKline has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash. The deal gives GSK access to Okairos genetic vaccine development platform, which uses viral vectors to spur a T-cell attack on a range of diseases such as hepatitis C, HIV, malaria, tuberculosis and human respiratory syncytial virus (RSV).


Okairos’ technology complements GSK’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines. The deal also includes a small number of early stage assets.

The acquisition reinforces GSK’s commitment to investment in innovative science. GSK’s vaccines business sits alongside pharmaceuticals and consumer healthcare as part of a balanced business and product portfolio capable of delivering sustainable sales growth.